跳到正文
原文
Medical Xpress·· 10 天前精选AI 评分80

实验性药物清除75%的胰腺肿瘤并增强免疫记忆

Experimental drug eliminates 75% of aggressive pancreatic tumors and enhances immune system memory

AI 导读

一项研究在Cancer Cell发表,描述了一种实验性药物FEBP-sTβRII,可清除胰腺肿瘤并阻止乳腺癌转移。该药物在多种癌症模型中表现出色,增强免疫记忆,为免疫治疗提供新策略。

推荐理由

研究揭示了一种新药在多种癌症模型中的显著疗效,有望为免疫治疗提供新策略。

正文
Preclinical findings show experimental drug eliminates 75% of aggressive pancreatic tumors and enhances immune system memory to fight other cancers
Graphical abstract. Credit: Cancer Cell (2026). DOI: 10.1016/j.ccell.2026.10.007

Many solid tumors, including many cancers of the pancreas, breast, colon and lung, protect themselves with a dense wall of scar-like tissue. That wall keeps the immune system's cancer-killing T cells out. It is a major reason why immunotherapy drugs, which have transformed treatment for some patients, help only a minority of people with solid tumors.

A study published in Cancer Cell describes an experimental drug that breaks down this barrier from inside the tumor and lets T cells in to attack. In mice, the drug cleared aggressive pancreatic tumors, stopped breast cancer from spreading and left the animals with long-lasting immune memory. That memory protected against new tumors, including some different types of cancer.

The international study was led by Dr. Seong-Jin Kim and his team of scientists at MedPacto Inc. in Seoul, Korea. Co-author John J. Letterio, M.D., Ph.D., is director of the Angie Fowler Adolescent and Young Adult Cancer Institute at University Hospitals Rainbow Babies & Children's Hospital and director of the Developmental Therapeutics Program at Case Comprehensive Cancer Center, Case Western Reserve University.

One molecule behind the wall

Tumors flood their surroundings with a signaling molecule called TGF-β. In solid tumors of many kinds, it directs nearby support cells to build fibrous tissue, and it suppresses the immune cells that could attack the cancer.

Drugs that block TGF-β throughout the body have disappointed in clinical trials. Safe doses don't block enough of it inside the tumor, and higher doses disrupt TGF-β's normal role in healthy tissue.

A drug that finds the tumor

The team engineered a TGF-β blocker, called FEBP-sTβRII, with a tag that sticks to a form of the protein fibronectin that is abundant in tumors but rare in healthy adult tissue.

The researchers found this target at high levels in mouse models of breast, colon, lung, liver, prostate, pancreatic and brain cancers and melanoma, and in many human tumor types. Because so many cancers share it, the approach could apply across many solid tumors.

The drug gathers in the tumor and stays there for days. The same blocker without the tag had little effect on tumors. It also changed the activity of 693 genes in the blood, compared with just 25 for the targeted drug.

Turning the tumor's neighborhood against the cancer

Once the barrier loosened, killer T cells moved into the tumor. They released a signal called interferon-gamma that converted the tumor's own support cells and nearby immune cells into allies. These cells began displaying pieces of the cancer to the immune system, fueling a self-reinforcing attack. The team saw this reprogramming in both pancreatic tumors and melanoma.

This is a distinct way to switch on tumor immunity. Current immunotherapies release the brakes on T cells. This approach also rebuilds the environment around the tumor so the immune system can reach the cancer and recognize it.

Results across cancer types

  • Pancreatic cancer: The drug worked in three different mouse models. In one aggressive model, tumors disappeared in 75% of treated mice, and seven of eight were still alive 270 days after treatment ended.
  • Triple-negative breast cancer: In a highly metastatic model, the drug slowed tumor growth, prevented spread to the lungs and extended survival. Standard immunotherapy and untargeted TGF-β blockers gave little or no benefit.
  • Combination therapy: Added to an existing immunotherapy drug (anti-PD-1), it nearly eradicated pancreatic tumors that resist that drug alone.
  • Lasting memory: Cured mice rejected the same cancer when it was reintroduced months later. Many also rejected bladder and lung tumors they had never encountered.
  • Transferable protection: T cells from cured mice protected cancer-free mice against bladder cancer.

"TGF-β helps build the defenses of many solid tumors, so this approach has the potential to reach well beyond a single cancer," said Letterio. "By delivering the blocker directly to the tumor, we don't just open the door to T cells. We appear to be teaching the immune system lessons it remembers long after the tumor is gone, and in some cases those lessons protect against other cancers."

What comes next

The findings point to a strategy for solid tumors that resist current immunotherapy, alone or in combination with existing immunotherapy drugs. The immune pattern the drug created in mice resembles patterns seen in patients who responded to immunotherapy for melanoma, gastric cancer and pancreatic cancer. Measuring the drug's target in a patient's tumor could help identify who is most likely to benefit.

"This study shows that where you block TGF-β matters as much as whether you block it," said senior author Kim, Ph.D., of MedPacto and the GILO Institute.

A version of the drug designed for humans has entered safety testing, with clinical trials planned for 2027. These human trials are designed to demonstrate whether the drug is safe and effective in patients with solid tumors refractory to other standard therapies.

Publication details

Dong Woo Kang et al., A stroma-sensing TGF-β blockade reprograms CAF-myeloid niches to induce durable tumor immunity, Cancer Cell (2026). DOI: 10.1016/j.ccell.2026.10.007

Journal information: Cancer Cell

Who's behind this story?

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Experimental drug eliminates 75% of aggressive pancreatic tumors and enhances immune system memory (2026, November 10) retrieved 10 November 2026 from https://medicalxpress.com/news/2026-11-experimental-drug-aggressive-pancreatic-tumors.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com